Holen Sie sich die Stockscreener-App
6.18
8.44%
-0.57
Handel nachbörslich:
6.17
-0.010
-0.16%
Schlusskurs vom Vortag:
$6.75
Offen:
$6.65
24-Stunden-Volumen:
203.57K
Relative Volume:
0.21
Marktkapitalisierung:
$151.69M
Einnahmen:
$251.00K
Nettoeinkommen (Verlust:
$-83.87M
KGV:
-1.8013
EPS:
-3.4309
Netto-Cashflow:
$-79.34M
1W Leistung:
+7.67%
1M Leistung:
+54.50%
6M Leistung:
+142.35%
1J Leistung:
+10.36%
1-Tages-Spanne:
$5.9523
$6.76
1-Wochen-Bereich:
$5.48
$7.7542
52-Wochen-Spanne:
$1.47
$7.7542
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Firmenname
Artiva Biotherapeutics Inc
Sektor
Branche
Telefon
(858) 267-4467
Adresse
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
6.18 | 165.68M | 251.00K | -83.87M | -79.34M | -3.4309 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Eingeleitet | Jefferies | Buy |
| 2024-08-13 | Eingeleitet | Needham | Buy |
| 2024-08-13 | Eingeleitet | TD Cowen | Buy |
| 2024-08-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Artiva Biotherapeutics Inc Aktie (ARTV) Neueste Nachrichten
Artiva Biotherapeutics (NASDAQ:ARTV) Given Buy Rating at Needham & Company LLC - Defense World
Artiva Biotherapeutics, Inc. 2025 Annual Report: Business Overview, Risk Factors, and Strategic Outlook - Minichart
Artiva Biotherapeutics' (ARTV) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Artiva: Sufficient Cash Runway to 2027 Supports Buy Rating Ahead of Key 2026 RA Efficacy Readouts - TipRanks
ARTV: AlloNK shows promise in refractory RA as clinical and financial milestones approach in 2026 - TradingView
Artiva Biotherapeutics 10-K: Revenue $0.0M, Net Loss $(83.9)M — Cash $108.0M - TradingView
ARTV: 2025 net loss widened to $83.9M as R&D spending increased; cash runway extends into Q2 2027 - TradingView
Artiva Biotherapeutics posts 2025 results, prepares for RA clinical data in early 2026 - Traders Union
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Growth Value: Is Stantec Inc on track to beat earningsWeekly Volume Report & Expert Curated Trade Ideas - baoquankhu1.vn
What insider trading reveals about Artiva Biotherapeutics Inc. stock2026 Price Swings & Advanced Swing Trade Entry Plans - Naître et grandir
Dow Update: Does Artiva Biotherapeutics Inc have consistent dividend growthWeekly Gains Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update - MarketBeat
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewswire
Artiva Biotherapeutics Appoints Thad Huston as Chief Financial Officer - The Globe and Mail
Artiva Biotherapeutics appoints Thad Huston as chief financial officer - Investing.com Australia
Artiva Biotherapeutics appoints Thad Huston as chief financial officer By Investing.com - Investing.com South Africa
Artiva Biotherapeutics, Inc. Appoints Thad Huston as Principal Financial Officer and Principal Accounting Officer, Effective from February 18, 2026 - marketscreener.com
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant - The Globe and Mail
Artiva Biotherapeutics Announces Appointment Of Thad Huston As CFO - TradingView
Artiva Biotherapeutics Announces Appointment of Thad Huston - GlobeNewswire
Is Artiva Biotherapeutics Inc. on track to beat earningsJuly 2025 Retail & Daily Profit Maximizing Tips - mfd.ru
Artiva Biotherapeutics Inc. (ARTV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Can Artiva Biotherapeutics Inc. keep up with sector leaders2025 Institutional Moves & AI Driven Stock Movement Reports - mfd.ru
Will Artiva Biotherapeutics Inc. benefit from rate cutsJuly 2025 Weekly Recap & Consistent Profit Alerts - mfd.ru
Artiva Biotherapeutics appoints pharma veteran Elaine Sorg to board By Investing.com - Investing.com India
Earnings Miss: Does Artiva Biotherapeutics Inc. have consistent dividend growthWeekly Stock Report & Precise Trade Entry Recommendations - mfd.ru
Artiva Biotherapeutics Adds Veteran Executive Elaine Sorg to Board - The Globe and Mail
Artiva Biotherapeutics appoints pharma veteran Elaine Sorg to board - Investing.com Australia
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors - Bitget
AtaiBeckley Appoints Michael Faerm as Chief Financial Officer - The Manila Times
Sell Signal: Is LINKBANCORP Inc a defensive stockJuly 2025 PreEarnings & High Yield Equity Trading Tips - baoquankhu1.vn
Aug Momentum: Does Artiva Biotherapeutics Inc have consistent dividend growth2025 Key Lessons & Precise Buy Zone Tips - baoquankhu1.vn
Will Artiva Biotherapeutics Inc. stock benefit from sector rotation2025 Dividend Review & Real-Time Buy Signal Notifications - mfd.ru
Can Artiva Biotherapeutics Inc. stock continue upward trendWeekly Loss Report & Free High Accuracy Swing Entry Alerts - mfd.ru
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Short Interest Down 28.5% in January - MarketBeat
Artiva Biotherapeutics, Inc. (RTVA.US) Latest News & Headlines - Longbridge
Is Artiva Biotherapeutics Inc. stock risky to hold nowJuly 2025 Momentum & Long-Term Growth Portfolio Plans - mfd.ru
Published on: 2026-02-12 04:11:50 - mfd.ru
Will Artiva Biotherapeutics Inc. outperform its industry peersPortfolio Update Report & Community Driven Trade Alerts - mfd.ru
Is Artiva Biotherapeutics Inc. stock a good pick for beginnersQuarterly Portfolio Review & AI Optimized Trading Strategy Guides - mfd.ru
Can Artiva Biotherapeutics Inc. stock outperform in a bear marketForecast Cut & Low Risk Investment Opportunities - mfd.ru
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $19.00 Average PT from Brokerages - Defense World
ARTV Stock Price and Chart — NASDAQ:ARTV - TradingView
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Artiva Biotherapeutics executes RSU exchange for employees - MSN
Trading Action: Is Artiva Biotherapeutics Inc stock a good pick for beginnersJuly 2025 Momentum & Community Consensus Trade Signals - baoquankhu1.vn
Hedge Fund Bets: Is CFRPRB stock heavily shortedTreasury Yields & Technical Pattern Recognition Alerts - baoquankhu1.vn
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decline in Short Interest - MarketBeat
Pharma News: Can AGMH outperform under higher oil pricesTrade Exit Report & Technical Entry and Exit Tips - baoquankhu1.vn
Finanzdaten der Artiva Biotherapeutics Inc-Aktie (ARTV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):